CN1146544C - 吡唑甲酸类衍生物、其制备方法和含有它们的药物组合物 - Google Patents
吡唑甲酸类衍生物、其制备方法和含有它们的药物组合物 Download PDFInfo
- Publication number
- CN1146544C CN1146544C CNB008054681A CN00805468A CN1146544C CN 1146544 C CN1146544 C CN 1146544C CN B008054681 A CNB008054681 A CN B008054681A CN 00805468 A CN00805468 A CN 00805468A CN 1146544 C CN1146544 C CN 1146544C
- Authority
- CN
- China
- Prior art keywords
- compound
- treatment
- bromophenyl
- ethyl
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
- C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/78—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
- C07C251/80—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明涉及是大麻素CB1受体强效拮抗剂的N-哌啶子基-5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基吡唑-3-甲酰胺、其盐和溶剂化物。其制备方法包括令5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基吡唑-3-甲酸的官能衍生物与1-氨基哌啶反应、随后选择性地成盐。
Description
技术领域
本发明涉及新的吡唑衍生物、其盐和溶剂化物,其制备方法和含有它们的药物组合物。
背景技术
专利申请EP-A-576 357、EP-A-658 546和WO-97/19036描述了具有大麻素(cannabino
de)受体亲和性的吡唑类衍生物。更加具体地,专利申请EP-A-656 354描述了对中柩大麻素受体具有非常良好亲和力的N-哌啶子基-5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-甲酰胺,其也称作SR141716,及其药学可接受盐。
文献中还公开了与SR141716类似的化合物,特别是N-哌啶子基-5-(4-溴苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-甲酰胺,此后称之为化合物A,该化合物是由B.F.Thomas等公开在J.Pharm.Exp.Therap.,1998,
285,285-292中。
大麻素类化合物的作用归因于其与中枢水平(Devane等,Mol.Pharmacol.,1988,
34,605-613)和外周水平(Nye等,Pharmacol.and Experimental Ther.,1985,
234,784-791;Kaminski等,1992,Mol.Pharmacol.,
42,736-743;Munro等,Nature 1993,
365,61-65)所存在的高亲和力特异受体之间的相互作用。
对大麻素受体具有特异性的合成配体的开发使该受体的表征成为可能,例如激动剂WIN 55212-2(J.Pharmacol.Exp.Ther.,1993,264,1352-1363)或CP55,940(J.Pharmacol.Exp.Ther.,1988,247,1046-1051)。CB1和CB2大麻素受体亚型的药理学公开在Pharmacol.Ther.,1997,
74,129-130。
发明内容
目前发现了新的N-哌啶子基-3-吡唑甲酰胺衍生物,其对大麻素受体的CB1亚型(CB1受体)具有非常好的亲和性并且作用时间长,其适用于那些被确认为大麻素类化合物参与其中的治疗领域。
按照一方面,本发明涉及下式的N-哌啶子基-5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基吡唑-3-甲酰胺及其药学可接受盐和溶剂化物:
按照另一方面,本发明涉及上式(I)化合物、其盐和溶剂化物的制备方法,其特征在于在有机溶剂中和碱的存在下,用1-氨基哌啶处理下式的5-(4-溴苯基)-1-(2-,4-二氯苯基)-4-乙基吡唑-3-甲酸的官能衍生物:
;并且令由此所得的化合物任选地转化为其一种盐或其一种溶剂化物。
该反应在碱性介质中,例如三乙胺的存在下,于惰性溶剂如二氯甲烷或四氢呋喃中进行。
可以利用的酸(II)的官能衍生物是酰氯,酸酐,混合酐,其中的烷基为直链或支链的C1-C4烷基酯;活化酯,例如对硝基苯基酯;或适当的活化游离酸,例如用N,N-二环己基碳二亚胺或用苯并三唑-N-氧代三(二甲基氨基)鏻(BOP)六氟磷酸盐活化。
所以,通过本发明方法的方式,由亚硫酰氯和式(II)的酸在惰性溶剂(如苯或甲苯)或氯代溶剂(如二氯甲烷、二氯乙烷或氯仿)中反应制得的式(II)的酰氯可以和醚(例如四氢呋喃或二噁烷),或酰胺(例如N,N-二甲基甲酰胺)在惰性气氛下、于0℃至溶剂回流点的温度下反应。
该实施方案的一种变化包括令氯代甲酸乙酯和式(II)的酸在碱如三乙胺的存在下反应,制得式(II)的酸的混合酸酐。
式(II)的酸可以按照下面的反应路线制备,其中:
LiHMDS=六甲基二硅氮锂
NBS=N-溴代琥珀酰亚胺
反应路线1
第一步按照J.Heterocyclic.Chem.,1989,
26,1389.所述方法进行。在倒数第二步中,所述吡唑的4-溴代甲基取代基向4-乙基的转化是按照J.Am.Chem.Soc.,1968,
90,5615所述方法进行。
所用的1-氨基哌啶是商购产品。
按照另一种方法可以制得式(VII)的酯和式(II)的酸,该方法构成本发明的另一主题。
利用以下反应路线举例说明这种方法,其中Alk表示(C1-C6)烷基和乙基。
反应路线2
这种方法的特征在于通过3-(4-溴代苯甲酰基)-2-(2-(2,4-二氯苯基)-亚肼基)-戊酸的烷基酯(IX)、优选乙酯的环化制备5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基吡唑-3-甲酸的烷基酯、优选乙酯。
该反应是在质子溶剂例如醇、如C1-C4醇、优选乙醇中,于室温至80℃的温度下、优选在回流乙醇中进行。
按照本发明,4-溴苯甲酰基-2-氧代戊酸(VIII)的烷基酯、优选乙酯在2,4-二氯苯基肼盐、优选盐酸盐的作用下制得3-(4-溴代苯甲酰基)-2-(2-(2,4-二氯苯基)-亚肼基)-戊酸的烷基酯,优选乙酯。
该反应是在质子溶剂、例如C1-C4醇、优选乙醇中进行。
按照本发明,溴代丁酰苯在LiHMDS的作用下并进而在2-(1-咪唑基)-2-氧代乙酸的烷基酯、优选乙酯的作用下制备4-溴代苯甲酰基-2-氧代戊酸的烷基酯、优选乙酯。
该反应是在有机溶剂如芳族溶剂或醚、优选甲基叔丁基醚中进行。该反应的第一步在低温下进行,例如0℃至-60℃的温度下进行,优选在-20℃的温度范围内;第二步在室温至-20℃、优选室温的温度下进行。
因此,按照反应路线2,5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基吡唑-3-甲酸(VII)的烷基酯的制备由4-溴代苯甲酰基-2-氧代戊酸(VIII)起始、在2,4-二氯苯基肼盐的作用下进行,随后环化。
溴代丁酰苯可商购。
J.Org.Chem.,1981,
46(1),211-213描述并且制备出2-(1-咪唑基)-2-氧代乙酸的乙酯。
本发明还包括一种由4-溴代苯甲酰基-2-氧代戊酸起始,在2,4-二氯苯基肼盐、优选其盐酸盐的作用下,于质子溶剂如C1-C4醇、优选乙醇中制备5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基吡唑-3-甲酸烷基酯、优选乙酯的方法。该反应在室温至80℃的温度下、优选在回流乙醇中进行。
下式的化合物:
其中Alk表示(C1-C6)烷基是新化合物并且构成本发明的一部分。优选地,Alk表示乙基。
根据常规方法,分离出按照本发明方法获得的式(I)的化合物,它们为游离碱的或盐或溶剂化物的形式。
式(I)的化合物的药学可接受盐包括与酸的加成盐,例如盐酸盐、氢溴酸盐、硫酸盐、硫酸氢盐、磷酸二氢盐、甲磺酸盐、甲基硫酸盐、草酸盐、马来酸盐、富马酸盐、2-萘磺酸盐、糖醛酸盐、葡糖酸盐、柠檬酸盐、羟乙基磺酸盐、对-甲苯磺酸盐或琥珀酸盐。
式(I)的化合物可以以其一种盐的形式分离,例如盐酸盐或草酸盐;在这样的情况中,通过用无机或有机碱中和该盐可以制备游离碱,例如氢氧化钠或氢氧化铵,三乙胺,或碱金属碳酸盐或碳酸氢盐,如碳酸钠或碳酸钾或碳酸氢钠或碳酸氢钾;并且转化为另一种盐,例如甲磺酸盐、富马酸盐或2-萘磺酸盐。
当获得的式(I)的化合物为游离碱的形式时,利用选择的酸在有机溶剂中通过处理进行成盐反应。通过将溶于如醚(如乙醚)或丙酮中的游离碱用在相同溶剂中的酸溶液处理,可以得到相应的盐,随后按照常规技术分离。
在Devane等,Mol.Pharmacol.,1988,
34,605-613所述的试验条件下,式(I)的化合物具有非常良好的体外CB1大麻素受体亲和力。
所以,按照本发明所述化合物对于人体CB1大麻素受体具有非常强的亲和力(Ki=5.4nM),其与在相同的条件下测定的SR141716对同样受体的亲和力(Ki=34nM)相比处于有利地位。
按照本发明的化合物再与N-哌啶子基-5-(4-溴苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-甲酰胺(化合物A)比较。在相同条件下测量,该化合物对人体CB1大麻素受体的亲和力反映为Ki值为8nM。
此外,对比下面三种化合物在存在于脑中的CB1受体的占有时间:
-按照本发明的式(I)的化合物
-SR141716
-化合物A
按照M.Rinaldi-Carmona等,Life Science,1995,
56,1941-1947所述技术,研究在小鼠体内、口服给予10mg/kg剂量的各个化合物以后进行。所得结果整理在下表内。
表1
受体的占有百分率% | ||
1小时 | 24小时 | |
式(I)的化合物 | 82% | 44% |
SR141716 | 69% | 4% |
化合物A | 89% | 4% |
令人惊奇地观察到,按照本发明所述式(I)的化合物是在其给药24小时后表现出高占有率(44%)的唯一化合物。
而且,式(I)的化合物的拮抗特性已被按照M.Rinaldi-Carmona等,J.Pharmacol.Exp.Ther.,1996,
278,871-878所述的腺苷酸环化酶的抑制模型中获得的结果证实。
特别是,本发明的化合物,无论是其天然形式或其一种药学可接受盐的形式,皆为CB1大麻素受体的强有力和选择性的拮抗剂。
按照本发明所述化合物的拮抗特性及其进入中枢神经系统的良好穿透性,已经被大麻素受体激动剂诱导的低体温的拮抗模型中所获取的结果验证。所以,按照本发明式(I)的化合物拮抗WIN55212-2在小鼠中引起的低体温,并且通过Pertwee R.G.等在Marijuana,
84,Ed.Harvey,D.Y.Oxford IRL Press,1985,263-277中所述的实验中口服DE50为0.3mg/kg。在这个实验中,比较了3种化合物的活性和作用时间。所得结果整理在下表内。
表2
诱导性低体温的拮抗作用
作用时间 | |||
口服DE50 | 口服剂量 | 24小时 | |
式(I)的化合物 | 0.3mg/kg | 1mg/kg | 有效 |
SR141716 | 0.4mg/kg | 1mg/kg10mg/kg | 无效有效 |
化合物A | 0.3mg/kg | 1mg/kg10mg/kg | 无效有效 |
发现本发明的化合物具有与现有技术的那些化合物可比的DE50,但其作用时间明显较长。
所以,在其给药24小时后,SR141716和化合物A仅在10mg/kg/口服的剂量下有效,按照本发明的式(I)的化合物在以低10倍的剂量(1mg/kg/口服)给药后24小时仍有效。
按照本发明式(I)的化合物的长效作用特别显著,并且代表了其用作医药产品的一个重要优越性。
式(I)的毒性适合于其作为药品的用途。
按照其另一方面,本发明涉及式(I)的化合物或其一种药学可接受盐或溶剂化物在制备用于治疗涉及CB1大麻素受体的疾病的药品中的应用。
譬如,并且以非限定方式,式(I)的化合物用作治疗精神病的药品,特别是用于治疗焦虑性疾病、心理疾病、谵妄性疾病、常见精神病,用于治疗精神分裂症和抑郁,以及用于治疗与使用治疗精神病物质有关的病症,特别是物品滥用和/或物质依赖性,包括酒精依赖和烟碱依赖。
按照本发明式(I)的化合物可以作为药品用于治疗神经病、偏头痛、紧张、身心失调源性机能紊乱、癫痫、运动性疾病,特别是运动障碍和帕金森氏病。
按照本发明式(I)的化合物还可以作为药物治疗记忆障碍、认知障碍,特别是治疗老年性痴呆和阿耳茨海默氏病;以及治疗注意力疾病或不眠症。此外,式(I)的化合物在神经变性疾病中可以是有效的神经保护剂。
按照本发明式(I)的化合物可以作为药物用于治疗食欲紊乱、瘾嗜(对糖、碳水化合物、药物、酒精或任何可食物质)和/或饮食疾病,特别是作为降低食欲的试剂或用于治疗肥胖或食欲过盛,以及用于II型糖尿病或非胰岛素依赖性糖尿病。此外,按照本发明式(I)的化合物可以作为药物用于治疗胃肠道疾病、腹泻性疾病、溃疡、呕吐、泌尿和膀胱疾病、心血管疾病、生育性疾病、炎症现象、感染性疾病并且作为抗癌化疗的药品。
按照本发明,式(I)的化合物首先特别适合于治疗精神病,特别是精神分裂症;治疗食欲紊乱和肥胖,治疗记忆和认知性障碍症;用于治疗酒精依赖或烟碱依赖,即戒酒精或戒烟。
按照一个方面,本发明涉及式(I)的化合物、其药学可接受盐和溶剂化物在治疗上述障碍症和疾病中的应用。
按照另一方面,本发明还涉及式(I)的化合物以其天然形式或放射标记的形式在人体或动物中作为药理学工具用于检测和标记CB1受体的应用。
本发明的化合物通常作为剂量单位给药。
所述剂量单位适宜配制为药物组合物,其中活性成分与药用赋形剂混合。
所以,按照一个方面,本发明涉及含有式(I)的化合物、其一种药学可接受盐或溶剂化物作为活性成分的药物组合物。
上述式(I)的化合物及其药学可接受盐或溶剂化物可以使用的日剂量为0.01至100mg/kg被治疗哺乳动物体重,优选日剂量为0.02至50mg/kg。在人体中,剂量可以优选为0.05至4000mg/天,更加特别为0.1至1000mg/天,这取决于被治疗个体的年龄和治疗的类型,即预防或治愈性治疗。尽管这些剂量是平常状况的实例,但它可以具有特例,其中适合采用更高剂量或较低剂量,并且这些剂量也属于本发明。按照常规,医师根据给药的方法和该患者的年龄、体重和反应可以判断出适合各患者的剂量。
在本发明用于口服、舌下、吸入、皮下、肌肉内、静脉内、透皮、局部或直肠给药的药物组合物中,活性成分可以以单位给药剂型、作为与常规药物载体的混合物给予动物和人体。适宜给药的单位剂型包括:口服途径剂型,如片剂、胶囊、粉末、颗粒剂和口服溶液或混悬液;舌下和经颊给药剂型,气溶胶,局部给药剂型,植入物;皮下、肌肉内、静脉内、鼻内或眼内给药剂型和直肠给药剂型。
在本发明的药物组合物中,活性成分一般配制为剂量单位,剂量单位中含有0.05至1000mg、适宜0.1至500mg和优选1至200mg的所述活性成分/剂量单位用于每日给药。
当固体组合物制备为片剂形式时,湿润剂如十二烷基硫酸钠可以加入微粉化或非微粉化活性成分中,并且将该整体与药用载体如二氧化硅、明胶、淀粉、乳糖、硬脂酸镁、滑石、阿拉伯胶等混合。片剂可以用蔗糖、多种聚合物或其它适宜材料包衣,或另外地处理它们使其具有持续或延迟的活性,令它们连续释放出预定量的活性成分。
通过将活性成分和稀释剂如二醇或甘油酯混合并且通过将所得混合物掺混在软或硬胶囊内可以制得明胶胶囊形式的制剂。
糖浆剂或酏剂形式的制剂可以含有活性成分与甜味剂、优选无热量甜味剂,作为防腐剂的对羟基苯甲酸甲酯和对羟基苯甲酸丙酯,以及鲜味剂和适当的着色剂。
水分散性粉末或颗粒剂可以含有活性成分,其与分散剂、湿润剂或助悬剂(如聚乙烯吡咯烷酮)以及甜味剂或矫味剂成为混合物。
为了直肠给药,可以采用栓剂,其可以利用于直肠温度下溶化的粘合剂如可可脂或聚乙二醇类制备。
为了肠胃外、鼻内或眼内给药,采用水混悬液、等渗盐水溶液或无菌液、可注射溶液,其中含有药学相容性分散剂和/或助溶剂,如聚丙二醇或聚乙二醇。
所以,为了制备可以静脉内注射的水溶液,可以利用助溶剂,例如醇,如乙醇,或二醇,如聚乙二醇或丙二醇,和亲水性表面活性剂,如吐温80(Tween80)。为了制备可肌肉内注射的油溶液,可以用甘油三酯或甘油酯溶解活性成分。
霜剂、软膏或凝胶可以用于局部给药。
为了透皮给药,可以采用多层形式或含有储库的贴剂,其中活性成分可以是醇溶液。
为了经吸入给药,采用气溶胶,其中含有例如脱水山梨糖醇三油酸酯或油酸以及三氯氟甲烷、二氯氟甲烷、二氯四氟乙烷或任何其它生物相容性抛射气体;还可以采用含有单独或与赋形剂结合的活性成分、粉末形式的体系。
活性成分也可以配制为微囊或微球的形式,任选地含有一种或多种载体或添加剂。
活性成分还可以是与环糊精形成的复合物形式,例如α-、β-或γ-环糊精、2-羟丙基-β-环糊精或甲基-β-环糊精。
在某些慢性治疗有效的缓释形式中,可以采用植入物。这些制备为油混悬液的形式或存在于等渗介质内的微球混悬液形式。
本发明的药物组合物在含有式(I)的化合物或其一种药学可接受盐或溶剂化物的同时还含有其它可以用来治疗上述障碍症或疾病的活性成分。
在本说明书中,使用下列缩写:
DCM:二氯甲烷
LiHMDS:六甲基二硅氮锂
TMSCl:氯代三甲基硅烷
APTS:对甲苯磺酸
NBS:N-溴代琥珀酰亚胺
MTBE:甲基叔丁基醚
TA:室温
F:熔点
CCM:薄层层析
RMN:核磁共振。RMN波谱在DMSO d6中在200MHz记录。
s:单峰;d:二重峰;t;三重峰;q:四重峰;
m:宽峰或多重峰;dd:双二重峰。
具体实施方式
制备例1
5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基吡唑-3-甲酸乙酯
A)4-(4-溴苯基)-3-甲基-4-氧-2-氧代丁烯酸乙酯的锂盐
氮气氛下,将21.6g的LiHMDS置于340ml无水乙醚中并且将该溶液冷却至-60℃,随后加入4g溶于150ml无水乙醚中的溴苯基·乙基酮。令该混合物升温至-30℃,随后加入17.53ml草酸乙酯。TA下搅拌过夜后,过滤出生成的沉淀,随后用乙醚清洗,真空下干燥。得到21.8g预期化合物。
B)4-(4-溴苯基)-2-[(2,4-二氯苯基)-亚肼基]-3-甲基-4-氧代丁酸乙酯
16.8g上步制备的化合物和12.5g 2,4-二氯苯基肼盐酸盐在150ml乙醇中混合在一起并且搅拌2.5小时。过滤生成的沉淀,用乙醇清洗,随后真空下干燥。得到16.24g的预期化合物。
C)5-(4-溴苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-甲酸乙酯
将16.24g上步制得的化合物在200ml乙酸中加热24小时,随后将反应介质倾入1升冰冷的水中;过滤出生成的沉淀,用水漂洗,真空下干燥。得到12.8g的预期化合物,由甲基环己烷重结晶该化合物,F=133℃。
D)4-溴代甲基-5-(4-溴苯基)-1-(2,4-二氯苯基)吡唑-3-甲酸乙酯
将12.8g上步制得的化合物置于130ml四氯化碳中并且加入5.27g的N-溴代琥珀酸亚胺,随后加入24mg的过氧化苯甲酰。该混合物加热回流4小时,随后过滤,真空下浓缩。残余物在硅胶上进行色谱层析,用甲苯/乙酸乙酯混合物(97/3;v/v)洗脱。得到7.24g预期化合物,
F=116℃
E)5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基吡唑-3-甲酸乙酯
氩气下,在100ml乙醚中引入2.26g CuBr产物混悬液,随后滴加-20℃的含有20ml稀释在20ml乙醚中的1.6M甲基锂醚溶液。-20℃下搅拌10分钟后,混悬液颜色消失,随后变澄清。使所得混合物冷却至-78℃,在30分钟内加入溶于100ml乙醚中的7g上步制得化合物的溶液,令该混合物升至室温。搅拌2小时后,通过加入饱和氯化铵水溶液水解该混合物。用乙醚提取所得混合物,用水洗涤,随后用饱和NaCl溶液洗涤。该溶液用MgSO4干燥,随后蒸发至干。残余物在硅胶上进行色谱层析,用甲苯/乙酸乙酯混合物洗脱(96/4;v/v)。得到3.7g预期化合物,F=108℃。
RMN:1,05ppm:t:3H;1,30ppm:t:3H;2,60ppm
:q:2H;4,30ppm:q:2H;7,15ppm:d:2H;
7,50-7,75ppm:m:5H.
制备例2
5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基吡唑-3-甲酸(II)
将3.6g制备例1获得的酯置于54ml的MeOH中,加入于6.85ml水中含有1.08g KOH的溶液。令反应介质加热回流3小时,随后真空下浓缩。残余物溶于冰冷的水中,用1N HCl酸化至pH=1,随后用DCM提取。得到3.3g的预期化合物,F=218℃。
RMN:1,10ppm:t:3H;2,70ppm:q:2H;7,25ppm
:d:2H;7,60-7,85ppm:m:5H.
制备例3
3-(4-溴代苯甲酰基)-2-氧代戊酸乙酯
将247g 4-溴代丁酰苯在1500ml MTBE中的溶液加入存在于2500ml MTBE中的210g LiHMDS溶液,同时保持温度-20℃。在此温度下搅拌3小时后,10℃下在1小时内加入210g存在于1000ml MTBE中的2-(1-咪唑基)-2-氧代乙酸乙酯,令该混合物在室温下搅拌18小时。过滤生成的锂盐,随后悬浮在800ml的MTBE中。向该混悬液中加入800ml的6N盐酸。通过滗析分离各相后,乙醚相用1000ml水洗涤4次,随后减压下浓缩。分离预期化合物(263g)。根据RMN分析,它是含有8%4-溴丁酰苯起始原料的混合物。
RMN:0,86ppm:t:3H;1,10ppm:t:3H;1,83ppm
:mt:2H;4,15ppm:q:2H;5,19ppm:t:1H;
7,70ppm:d:2H;7,98ppm:d:2H.
制备例4
5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基吡唑-3-甲酸乙酯
A)3-(4-溴代苯甲酰基)-2-(2-(2,4-二氯苯基)-亚肼基)戊酸乙酯
在1200ml的乙醇中制备155g 2,4-二氯苯基肼盐酸盐的混悬液,室温下加入存在于1000ml乙醇中的263g制备例3的化合物。
通过过滤分离出生成的小部分中间体并且定性。
RMN:0,92ppm:t:3H;1,04ppm:t:3H;1,89ppm
:mt:2H;4,16ppm:q:2H;4,76ppm:t:1H;
7,42ppm:mt:2H;7,60ppm:s:1H;7,75ppm:d:
2H;7,93ppm:d:2H;12,31ppm:s:1H.
B)5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基吡唑-3-甲酸乙酯
将所得混悬液回流4小时,随后室温下搅拌18小时。过滤出生成的产物,随后在50℃的真空下干燥,得到预期化合物(247g),F=108℃。
RMN:1,07ppm:t:3H;1,28ppm:t:3H;2,58ppm
:q:2H;4,32ppm:q:2H;7,16ppm:d:2H;7,53
ppm:dd:1H;7,59ppm:d:2H;7,73ppm:d+
小的d:2H.
实施例1
N-哌啶子基-5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基吡唑-3-甲酰胺
A)5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基吡唑-3-甲酰氯
将3.2g上步制得的酸置于32ml甲苯中成为混悬液,加入1.6ml亚硫酰氯,随后该混合物回流加热3小时。反应介质真空下浓缩,进而溶于甲苯。重复操作数次。得到3.3g预期化合物。
B)N-哌啶子基-5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基吡唑-3-甲酰胺
氮气下在20ml的DCM中制备0.23ml N-氨基哌啶和0.29ml三乙胺的溶液,冷却至0℃-5℃内。加入存在于20ml DCM中的0.8g上步制得的酰氯。室温下静置过夜,将所得混合物倾入冰冷的水中,并滗析。有机相用DCM提取,随后用水洗、用5%Na2CO3溶液和用饱和NaCl溶液洗涤。把所得溶液蒸发至干,随后残余物在硅胶上进行色谱层析,用甲苯/AcOEt混合物(80/20;v/v)洗脱。得到0.52g预期化合物,F=113℃。
RMN:1,05ppm:t:3H;1,25-1,65ppm:m:6H;2,65
ppm:q:2H;2,80ppm:m:4H;7,15ppm:d:2H;
7,50-7,80ppm:m:5H;9,10ppm:s:1H.
实施例2
N-哌啶子基-5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基吡唑-3-甲酰胺
A)5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基吡唑-3-甲酰氯
在1200ml的甲苯中制备含有97g亚硫酰氯和118g制备例4的化合物的混合物,逐步加热至回流,随后在回流下维持3小时。浓缩反应介质。
B)N-哌啶子基-5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基吡唑-3-甲酰胺
将生成的酰氯溶于380ml的甲基环己烷中,加入存在于218mlTHF中的2.8g三乙胺。令该混合物保持在50℃。
在34ml的甲基环己烷中制备30g N-氨基哌啶和28g三乙胺的溶液,冷却至10℃,缓慢加入含有酰氯的混合物。10℃下搅拌2小时后,过滤出生成的产物,溶于2000ml的DCM中,用2000ml水洗涤2次。产物由4500ml的甲基环己烷重结晶,随后过滤出并且干燥。得到125g的预期化合物。
Claims (8)
3.下式的化合物及其官能衍生物
4.按照权利要求3的下式化合物,
其中Alk表示(C1-C4)烷基。
5.用于治疗涉及CB1大麻素受体的疾病的药物组合物,含有权利要求1所述的化合物作为活性成分。
6.按照权利要求5的药物组合物,在单位剂型中含有0.1至1000mg活性成分,其中活性成分与至少一种药用赋形剂混合。
7.按照权利要求1的化合物在制备用于治疗涉及CB1大麻素受体的疾病的药品中的应用。
8.按照权利要求7的化合物的应用,其所述药品用于治疗精神病,用于治疗食欲紊乱和肥胖,用于治疗记忆和认知性障碍症;用于治疗酒精依赖或用于烟草戒断。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9901201A FR2789078B3 (fr) | 1999-02-01 | 1999-02-01 | Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
FR99/01201 | 1999-02-01 | ||
FR9910166A FR2789079B3 (fr) | 1999-02-01 | 1999-08-02 | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
FR99/10166 | 1999-08-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1346349A CN1346349A (zh) | 2002-04-24 |
CN1146544C true CN1146544C (zh) | 2004-04-21 |
Family
ID=26234792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008054681A Expired - Fee Related CN1146544C (zh) | 1999-02-01 | 2000-01-28 | 吡唑甲酸类衍生物、其制备方法和含有它们的药物组合物 |
Country Status (37)
Country | Link |
---|---|
US (3) | US6432984B1 (zh) |
EP (1) | EP1150961B1 (zh) |
JP (1) | JP3794925B2 (zh) |
KR (1) | KR100425405B1 (zh) |
CN (1) | CN1146544C (zh) |
AR (1) | AR020558A1 (zh) |
AT (1) | ATE252562T1 (zh) |
AU (1) | AU754771B2 (zh) |
BG (1) | BG65193B1 (zh) |
BR (1) | BR0007895A (zh) |
CA (1) | CA2358885C (zh) |
CO (1) | CO5160257A1 (zh) |
CZ (1) | CZ297667B6 (zh) |
DE (1) | DE60006070T2 (zh) |
DK (1) | DK1150961T3 (zh) |
EE (1) | EE04343B1 (zh) |
ES (1) | ES2208267T3 (zh) |
FR (1) | FR2789079B3 (zh) |
HK (1) | HK1039329A1 (zh) |
HR (1) | HRP20010564B1 (zh) |
HU (1) | HUP0201278A3 (zh) |
ID (1) | ID29534A (zh) |
IL (2) | IL144198A0 (zh) |
IS (1) | IS2448B (zh) |
ME (2) | MEP11408A (zh) |
NO (1) | NO319824B1 (zh) |
NZ (1) | NZ512886A (zh) |
PE (1) | PE20001493A1 (zh) |
PL (1) | PL198422B1 (zh) |
PT (1) | PT1150961E (zh) |
RS (1) | RS50209B (zh) |
RU (1) | RU2216542C2 (zh) |
SK (1) | SK284203B6 (zh) |
TR (1) | TR200102054T2 (zh) |
TW (1) | TW581764B (zh) |
UA (1) | UA66900C2 (zh) |
WO (1) | WO2000046209A1 (zh) |
Families Citing this family (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
FR2799124B1 (fr) * | 1999-10-01 | 2004-08-13 | Sanofi Synthelabo | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
US7393842B2 (en) * | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
FR2804604B1 (fr) * | 2000-02-09 | 2005-05-27 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac |
FR2809621B1 (fr) * | 2000-05-12 | 2002-09-06 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques |
US20020091114A1 (en) | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
BR0211705A (pt) * | 2001-08-06 | 2004-09-28 | Astrazeneca Ab | Processo para a preparação de uma dispersão estável de partìculas sólidas em um meio aquoso, dispersão estável aquosa, partìcula sólida, composição farmacêutica, método para a inibição do amadurecimento de ostwald em uma dispersão de partìculas sólidas substancialmente insolúveis em água em um meio aquoso, e, uso de um inibidor |
US7109216B2 (en) * | 2001-09-21 | 2006-09-19 | Solvay Pharmaceuticals B.V. | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
RU2299199C2 (ru) | 2001-09-21 | 2007-05-20 | Солвей Фармасьютикалс Б.В. | Новые производные 4,5-дигидро-1h-пиразола, имеющие cb1-антагонистическую активность |
TWI231757B (en) * | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
CN1529595A (zh) | 2001-09-21 | 2004-09-15 | ������ҩ������˾ | 具有效cb1-拮抗活性的4,5-2氢-1h-吡唑衍生物 |
WO2003075917A1 (en) | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
AR038966A1 (es) | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 |
FR2837706A1 (fr) * | 2002-03-28 | 2003-10-03 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles |
AU2003225964B2 (en) * | 2002-03-28 | 2008-11-20 | Merck Sharp & Dohme Corp. | Substituted 2,3-diphenyl pyridines |
US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
US6972291B2 (en) * | 2002-07-02 | 2005-12-06 | Bernstein Richard K | Method for reducing food intake |
GB0216700D0 (en) * | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
KR100741231B1 (ko) | 2002-07-29 | 2007-07-19 | 에프. 호프만-라 로슈 아게 | 신규 벤조다이옥솔 |
US7319110B2 (en) * | 2002-09-19 | 2008-01-15 | Solvay Pharmaceuticals B.V. | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity |
SE0203070D0 (en) | 2002-10-16 | 2002-10-16 | Astrazeneca Ab | Novel compounds |
EP1556373A1 (en) * | 2002-10-18 | 2005-07-27 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
FR2849032B1 (fr) * | 2002-12-23 | 2006-04-28 | Sanofi Synthelabo | Derive de 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n -(piperidin-1-yl)-1h-pyrazole-3-carboxamide, sa preparation, son application en therapeuthique |
GB0230087D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
WO2004060870A1 (en) * | 2003-01-02 | 2004-07-22 | F. Hoffmann-La Roche Ag | Novel cb 1 receptour inverse agonists |
ATE400571T1 (de) | 2003-01-02 | 2008-07-15 | Hoffmann La Roche | Pyrrolyl-thiazole und ihre verwendung als inverse agonisten des cb 1 rezeptors |
GB0302672D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
GB0302673D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
GB0302671D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US20060172019A1 (en) * | 2003-03-07 | 2006-08-03 | Ralston Stuart H | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
JP4041153B2 (ja) * | 2003-05-07 | 2008-01-30 | ファイザー・プロダクツ・インク | カンナビノイド受容体リガンドとその使用 |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
SE0301698D0 (sv) * | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
SE0301701D0 (sv) * | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
SE0301699D0 (sv) * | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
EP1641779A1 (en) * | 2003-06-18 | 2006-04-05 | AstraZeneca AB | 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator. |
GB0314057D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314261D0 (en) * | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
CA2528785A1 (en) | 2003-06-20 | 2005-01-06 | Matthias Heinrich Nettekoven | 2-amidobenzothiazoles as cb1 receptor inverse agonists |
US7517900B2 (en) | 2003-10-10 | 2009-04-14 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
FR2861303A1 (fr) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
FR2861301B1 (fr) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
FR2861300B1 (fr) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
FR2861302A1 (fr) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
AU2004299198A1 (en) | 2003-12-08 | 2005-06-30 | F. Hoffmann-La Roche Ag | Novel thiazole derivates |
CA2553970A1 (en) | 2004-01-28 | 2005-08-18 | F. Hoffmann-La Roche Ag | Spiro-benzodioxoles and their use as cb1 antagonists |
US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
FR2866340B1 (fr) * | 2004-02-13 | 2006-11-24 | Sanofi Synthelabo | Derives d'oxazole, leur preparation et leur utilisation en therapeutique. |
US20090149463A1 (en) * | 2004-02-20 | 2009-06-11 | Leifeng Cheng | Therapeutic agents |
EP1574211A1 (en) | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
FR2867685B1 (fr) * | 2004-03-17 | 2008-05-23 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement de la bronchite chronique et de la broncho-pneumopathie chronique obstructive |
BRPI0510679A (pt) | 2004-05-10 | 2007-12-26 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação dos receptores de cb1 e utilização desses compostos |
ITMI20041032A1 (it) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Compositi farmaceutici |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
WO2006025069A2 (en) | 2004-07-12 | 2006-03-09 | Cadila Healthcare Limited | Tricyclic pyrazole derivatives as cannabinoid receptor modulators |
US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
EP1807070A1 (en) * | 2004-09-29 | 2007-07-18 | Schering Corporation | Combinations of substituted azetidinones and cb1 antagonists |
ATE399156T1 (de) | 2004-10-27 | 2008-07-15 | Hoffmann La Roche | Neue indol- oder benzimidazol-derivate |
AU2005304039A1 (en) | 2004-11-09 | 2006-05-18 | F. Hoffmann-La Roche Ag | Dibenzosuberone derivatives |
CA2589483C (en) | 2004-12-03 | 2013-10-29 | Schering Corporation | Substituted piperazines as cb1 antagonists |
WO2006067443A1 (en) * | 2004-12-23 | 2006-06-29 | Astrazeneca Ab | Therapeutic agents |
FR2880023B1 (fr) | 2004-12-23 | 2007-02-23 | Sanofi Aventis Sa | Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique |
CA2594488C (en) * | 2005-01-10 | 2015-04-28 | University Of Connecticut | Novel heteropyrrole analogs acting on cannabinoid receptors |
US8853205B2 (en) | 2005-01-10 | 2014-10-07 | University Of Connecticut | Heteropyrrole analogs acting on cannabinoid receptors |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
FR2881744B1 (fr) | 2005-02-09 | 2007-04-27 | Sanofi Aventis Sa | Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique |
FR2882261B1 (fr) * | 2005-02-21 | 2009-02-06 | Sanofi Aventis Sa | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 |
FR2882264A1 (fr) * | 2005-02-21 | 2006-08-25 | Sanofi Aventis Sa | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 |
UY29386A1 (es) * | 2005-02-21 | 2006-10-02 | Sanofi Aventis | Utilizción de rimonabant para la preparación de medicamentos útiles en la prevención y el tratamiento de la diabetes de tipo2. |
FR2882262B1 (fr) * | 2005-02-23 | 2007-04-06 | Sanofi Aventis Sa | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales |
FR2882263B1 (fr) * | 2005-02-23 | 2007-04-06 | Sanofi Aventis Sa | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales |
FR2882931B1 (fr) * | 2005-03-14 | 2007-05-18 | Sanofi Aventis Sa | Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique |
DK1868999T3 (da) | 2005-04-06 | 2009-08-17 | Hoffmann La Roche | Pyridin-3-carboxamidderivater som omvendte CB1-agonister |
WO2006129193A2 (en) * | 2005-05-27 | 2006-12-07 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
GB0514738D0 (en) * | 2005-07-19 | 2005-08-24 | Astrazeneca Ab | Therapeutic agents |
GB0514739D0 (en) * | 2005-07-19 | 2005-08-24 | Astrazeneca Ab | Therapeutic agents |
CA2617654A1 (en) * | 2005-08-04 | 2007-02-08 | Pfizer Limited | Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds |
CA2518579A1 (en) * | 2005-08-05 | 2007-02-05 | University Technologies International Inc. | Method for appetite suppression |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
CN100999517B (zh) * | 2006-01-11 | 2010-12-15 | 北京摩力克科技有限公司 | 吡唑甲酰胺衍生物,药物组合物和其制备方法 |
CA2637565A1 (en) | 2006-01-18 | 2007-07-26 | Schering Corporation | Cannibinoid receptor modulators |
EA200801738A1 (ru) * | 2006-02-23 | 2008-12-30 | Пфайзер Лимитед | Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа |
AU2007226673A1 (en) * | 2006-03-10 | 2007-09-20 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
RU2424242C2 (ru) | 2006-03-30 | 2011-07-20 | Айрм Ллк | Азолопиримидины в качестве ингибиторов активности каннабиноидного рецептора 1 |
WO2007121687A1 (fr) * | 2006-04-26 | 2007-11-01 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | Dérivés du 4-méthyl-1h-diaryl pyrazole et leur utilisation comme médicaments |
CN101062919B (zh) * | 2006-04-26 | 2012-08-15 | 中国人民解放军军事医学科学院毒物药物研究所 | 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途 |
FR2902008A1 (fr) * | 2006-06-07 | 2007-12-14 | Sanofi Aventis Sa | Utilisation d'un antagoniste des recepteurs cb1 aux cannabinoides pour la preparation de medicaments utiles pour la prevention et le traitement de l'hypertrophie begnine de la prostate |
US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
BRPI0716134A2 (pt) | 2006-09-07 | 2013-09-17 | Nycomed Gmbh | tratamento de combinaÇço para diabetes mellitus |
EP2061783A2 (en) * | 2006-09-11 | 2009-05-27 | Hetero Drugs Limited | Improved process for rimonabant |
US7781593B2 (en) * | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
US7875647B2 (en) | 2006-09-29 | 2011-01-25 | Green Cross Corporation | Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists |
KR20090064478A (ko) | 2006-11-13 | 2009-06-18 | 화이자 프로덕츠 인크. | 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도 |
FR2909090B1 (fr) | 2006-11-23 | 2009-01-09 | Sanofi Aventis Sa | Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique. |
CN101663262B (zh) | 2006-12-01 | 2014-03-26 | 百时美施贵宝公司 | 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物 |
JP5437812B2 (ja) | 2006-12-18 | 2014-03-12 | 7ティーエム ファーマ エイ/エス | Cb1受容体モジュレーター |
FR2911136B1 (fr) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique. |
GB0702862D0 (en) * | 2007-02-14 | 2007-03-28 | Univ Aberdeen | Therapeutic compounds |
WO2008102367A1 (en) * | 2007-02-19 | 2008-08-28 | Darmesh Mahendrabhai Shah | Process for preparation of pyrazole derivatives |
FR2913018A1 (fr) * | 2007-02-23 | 2008-08-29 | Sanofi Aventis Sa | Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs |
US20100197564A1 (en) * | 2007-04-19 | 2010-08-05 | Schering Corporation | Diaryl morpholines as cb1 modulators |
MX2009013354A (es) | 2007-06-04 | 2010-07-06 | Univ Ben Gurion | Compuestos de triarilo y composiciones que los contienen. |
WO2009005671A2 (en) * | 2007-06-28 | 2009-01-08 | Schering Corporation | Substituted piperazines as cb1 antagonists |
RU2010102478A (ru) * | 2007-06-28 | 2011-08-10 | Интэрвэт Интэрнэшнл Б.Ф. (NL) | Замещенные пиперазины как антагонисты св1 |
FR2919861A1 (fr) * | 2007-08-06 | 2009-02-13 | Sanofi Aventis Sa | Le solvate d'isopranol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
US8133904B2 (en) * | 2007-09-07 | 2012-03-13 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
WO2010013240A1 (en) | 2008-07-31 | 2010-02-04 | Dekel Pharmaceuticals Ltd. | Compositions and methods for treating inflammatory disorders |
AU2009278838B2 (en) * | 2008-08-06 | 2013-07-25 | Pfizer Limited | Diazepine and diazocane compounds as MC4 agonists |
WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
US10053444B2 (en) | 2009-02-19 | 2018-08-21 | University Of Connecticut | Cannabinergic nitrate esters and related analogs |
US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
WO2013068371A1 (en) | 2011-11-08 | 2013-05-16 | Intervet International B.V. | Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists |
AU2014347668A1 (en) | 2013-11-05 | 2016-05-19 | Ben-Gurion University Of The Negev Research And Development Authority | Compounds for the treatment of diabetes and disease complications arising from same |
CA3125847A1 (en) | 2020-07-27 | 2022-01-27 | Makscientific, Llc | Process for making biologically active compounds and intermediates thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2713225B1 (fr) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
FR2741621B1 (fr) * | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
-
1999
- 1999-08-02 FR FR9910166A patent/FR2789079B3/fr not_active Expired - Lifetime
-
2000
- 2000-01-28 CA CA002358885A patent/CA2358885C/en not_active Expired - Fee Related
- 2000-01-28 ID IDW00200101603A patent/ID29534A/id unknown
- 2000-01-28 HU HU0201278A patent/HUP0201278A3/hu unknown
- 2000-01-28 DK DK00901661T patent/DK1150961T3/da active
- 2000-01-28 EP EP00901661A patent/EP1150961B1/fr not_active Expired - Lifetime
- 2000-01-28 IL IL14419800A patent/IL144198A0/xx active IP Right Grant
- 2000-01-28 WO PCT/FR2000/000194 patent/WO2000046209A1/fr active IP Right Grant
- 2000-01-28 BR BR0007895-6A patent/BR0007895A/pt not_active IP Right Cessation
- 2000-01-28 PL PL350030A patent/PL198422B1/pl not_active IP Right Cessation
- 2000-01-28 RU RU2001121186/04A patent/RU2216542C2/ru not_active IP Right Cessation
- 2000-01-28 TR TR2001/02054T patent/TR200102054T2/xx unknown
- 2000-01-28 DE DE60006070T patent/DE60006070T2/de not_active Expired - Lifetime
- 2000-01-28 NZ NZ512886A patent/NZ512886A/xx not_active IP Right Cessation
- 2000-01-28 CN CNB008054681A patent/CN1146544C/zh not_active Expired - Fee Related
- 2000-01-28 ES ES00901661T patent/ES2208267T3/es not_active Expired - Lifetime
- 2000-01-28 AT AT00901661T patent/ATE252562T1/de active
- 2000-01-28 PE PE2000000066A patent/PE20001493A1/es not_active Application Discontinuation
- 2000-01-28 JP JP2000597279A patent/JP3794925B2/ja not_active Expired - Fee Related
- 2000-01-28 KR KR10-2001-7009572A patent/KR100425405B1/ko not_active IP Right Cessation
- 2000-01-28 ME MEP-114/08A patent/MEP11408A/xx unknown
- 2000-01-28 US US09/890,242 patent/US6432984B1/en not_active Expired - Lifetime
- 2000-01-28 PT PT00901661T patent/PT1150961E/pt unknown
- 2000-01-28 UA UA2001074905A patent/UA66900C2/uk unknown
- 2000-01-28 EE EEP200100399A patent/EE04343B1/xx not_active IP Right Cessation
- 2000-01-28 CZ CZ20012697A patent/CZ297667B6/cs not_active IP Right Cessation
- 2000-01-28 AR ARP000100386A patent/AR020558A1/es unknown
- 2000-01-28 RS YUP-539/01A patent/RS50209B/sr unknown
- 2000-01-28 ME MEP-2008-114A patent/ME00052B/me unknown
- 2000-01-28 SK SK1087-2001A patent/SK284203B6/sk not_active IP Right Cessation
- 2000-01-28 AU AU22989/00A patent/AU754771B2/en not_active Ceased
- 2000-01-31 TW TW089101649A patent/TW581764B/zh not_active IP Right Cessation
- 2000-01-31 CO CO00005429A patent/CO5160257A1/es unknown
-
2001
- 2001-07-08 IL IL144198A patent/IL144198A/en not_active IP Right Cessation
- 2001-07-13 IS IS6002A patent/IS2448B/is unknown
- 2001-07-26 HR HR20010564A patent/HRP20010564B1/xx not_active IP Right Cessation
- 2001-07-27 BG BG105749A patent/BG65193B1/bg unknown
- 2001-07-30 NO NO20013736A patent/NO319824B1/no not_active IP Right Cessation
-
2002
- 2002-01-29 HK HK02100712A patent/HK1039329A1/xx not_active IP Right Cessation
- 2002-06-07 US US10/165,140 patent/US6645985B2/en not_active Expired - Lifetime
-
2003
- 2003-06-05 US US10/455,220 patent/US20040039024A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1146544C (zh) | 吡唑甲酸类衍生物、其制备方法和含有它们的药物组合物 | |
CN1720225B (zh) | 具有5-羟色胺受体亲和性的n-芳基磺酰-3-取代吲哚及其制备方法和含有其的药物组合物 | |
CN1110968A (zh) | 取代的n-哌啶子基-吡唑-3-甲酰胺 | |
JP4519861B2 (ja) | 新規なアザ二環式誘導体、その製造方法、およびそれを含む医薬組成物 | |
CN1187330C (zh) | 吲哚衍生物、制备它们的方法、含有它们的药用组合物和它们的医疗应用 | |
CN1243723C (zh) | 作为fsad的nep抑制剂的n-苯丙基环戊基取代的戊二酰胺衍生物 | |
FR2875230A1 (fr) | Derives de pyrazole condense, leur preparation et leur application en therapeutique | |
CN1882541A (zh) | N-[苯基(烷基-2-哌啶基)甲基]苯甲酰胺衍生物,其制备和治疗用途 | |
CN1918121A (zh) | 用于治疗肥胖的吡咯-3-甲酰胺衍生物 | |
CN1337963A (zh) | 吡嗪并(氮杂)吲哚衍生物 | |
CN1331076A (zh) | 稠合的吡唑基化合物、包含该化合物的组合物及该化合物的应用 | |
CN1305465A (zh) | 芳基链烷酰基哒嗪化合物 | |
CN1203589A (zh) | 新的化合物 | |
CN1615297A (zh) | 治疗精神分裂症和抑郁等疾病的苯氧基-哌啶 | |
TW200927729A (en) | 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives | |
CN1040025A (zh) | 新的四氢苯并吲哚丙酸磺酰胺的制备 | |
EP0553016B1 (fr) | Nouveaux amides et sulfonamides naphtaleniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent | |
EP1507758B1 (fr) | Derives d'indole et leur utilisation en tant que ligands des recepteurs cb2 | |
CN1014058B (zh) | 制备2-吡咯烷酮衍生物的方法 | |
CN1768053A (zh) | 吡唑化合物 | |
CN1370154A (zh) | 氨基噻唑衍生物及其作为crf受体配体的用途 | |
CN1153766C (zh) | 新的硝酮化合物,其制备方法以及含有它们的药物组合物 | |
CN1077192A (zh) | 2-氧代喹啉衍生物 | |
CN1342148A (zh) | 用作因子Xa抑制剂的吡唑-3-酮衍生物 | |
CN1090629C (zh) | 新的杂环化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: SANOFI - AVENTIS Free format text: FORMER NAME OR ADDRESS: ST. SANOFI - SYNTHELABO CORPORATION |
|
CP03 | Change of name, title or address |
Address after: France Patentee after: Sanofi-Aventis Address before: France Patentee before: Sanofi-Synthelabo |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040421 Termination date: 20140128 |